Cyclic Glycine-Proline Improves Memory and Reduces Amyloid Plaque Load in APP/PS1 Transgenic Mouse Model of Alzheimer's Disease. (1st March 2023)

• Record Type: Journal Article
• Authors: Arora, Tushar; Sharma, Shiv K.
• Other Names: Abate Giulia Academic Editor.
• Is Part Of: International journal of alzheimer's disease. Volume 2023(2023)
• Publication Date: 2023-03-01
• Subjects: Alzheimer's disease -- Periodicals; 616.831005
• DOI: 10.1155/2023/1753791
• Languages: English
• ISSNs: 2090-8024

Abstract

Abstract : Alzheimer's disease (AD) is a neurodegenerative condition that is pathologically characterized by the presence of amyloid plaques and neurofibrillary tangles. Animal models of AD have been useful in understanding the disease process and in investigating the effects of compounds on pathology and behavior. APP/PS1 mice develop amyloid plaques and show memory impairment. Cyclic glycine-proline (cGP) is a cyclic dipeptide that is likely produced from a tripeptide, glycine-proline-glutamate, which itself is generated after proteolytic cleavage of insulin-like growth factor-1. Here, we show that cGP improves spatial memory and reduces amyloid plaque burden in APP/PS1 mice. The results thus suggest that cGP could potentially provide beneficial effects in AD.